Gain TherapeuticsGANX
13F holders, Q2 2025 (June 30)At the end of Q2 2025, 35 institutions reported holding Gain Therapeutics Inc. (GANX) in their 13F filings, up 2 from Q1 2025. 6 opened new positions and 4 sold out. The largest holders were Gotham Asset Management ($5.4M), Jones Financial Companies LLLP ($1.3M) and Greenlight Capital (DME Capital Management) ($1.0M). 4 famous investors held it, including David Einhorn (0.0% of Greenlight Capital (DME Capital Management)'s portfolio), Joel Greenblatt (0.0% of Gotham Asset Management's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Gain Therapeutics Inc.
- CUSIP
- 36269B105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $253K |
| Exits | 4 | $93K |
All 13F filers, Q1 2025 → Q2 2025: 1,147,244 shares bought and 170,075 shares sold, net +977,169 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 35 holders
| Gotham Asset Management | 0.03% | Add +59.7% | 245,896 | $5.4M |
| Jones Financial Companies LLLP | 0.00% | Add +58.3% | 676,888 | $1.3M |
| Greenlight Capital (DME Capital Management) | 0.04% | No change | 566,130 | $1.0M |
| Vanguard Group Inc. | 0.00% | Add +109.6% | 534,352 | $962K |
| Geode Capital Management, LLC | 0.00% | Add +2.9% | 290,462 | $523K |
| Marshall Wace, LLP | 0.00% | Add +41.0% | 276,433 | $498K |
| Cambridge Investment Research Advisors, Inc. | 0.00% | Add +201.7% | 179,500 | $323K |
| Citadel Advisors | 0.00% | Add +750.8% | 161,816 | $291K |
| BlackRock, Inc. | 0.00% | Add +33.3% | 112,507 | $203K |
| Northern Trust Corp. | 0.00% | No change | 100,170 | $180K |
| Renaissance Technologies | 0.00% | New | 94,000 | $169K |
| Susquehanna International Group, LLP | 0.00% | Reduce -7.5% | 79,551 | $143K |
| Morgan Stanley | 0.00% | Reduce -23.3% | 76,512 | $138K |
| State Street Corp. | 0.00% | No change | 71,137 | $128K |
| NorthCoast Asset Management LLC | 0.00% | No change | 47,578 | $86K |
| Dauntless Investment Group, LLC | 0.39% | Reduce -63.4% | 46,000 | $83K |
| Prelude Capital Management, LLC | 0.01% | No change | 35,820 | $64K |
| UBS Group AG | 0.00% | Reduce -24.7% | 32,635 | $59K |
| Bridgeway Capital Management, LLC | 0.00% | No change | 30,004 | $54K |
| Virtu Financial LLC | 0.00% | New | 23,801 | $43K |
| Benedict Financial Advisors Inc. | 0.01% | Add +25.0% | 22,500 | $41K |
| Sandhill Capital Partners LLC | 0.00% | No change | 15,400 | $28K |
| Gsa Capital Partners LLP | 0.00% | New | 12,756 | $23K |
| NewEdge Advisors, LLC | 0.00% | No change | 10,600 | $19K |
| Bison Wealth, LLC | 0.00% | No change | 10,750 | $19K |
| Group One Trading LLC | 0.00% | New | 6,401 | $12K |
| Simplex Trading, LLC | 0.00% | Add +64.3% | 5,657 | $10K |
| Creekmur Asset Management LLC | 0.00% | No change | 4,440 | $8K |
| MAI Capital Management | 0.00% | No change | 4,410 | $8K |
| Bank of America Corp. | 0.00% | Add +1.5% | 4,164 | $7K |
| Wells Fargo & Company | 0.00% | No change | 2,650 | $5K |
| Arax Advisory Partners | 0.00% | No change | 2,500 | $5K |
| Raymond James Financial Inc. | 0.00% | New | 2,300 | $4K |
| State of Wyoming | 0.00% | New | 1,194 | $2K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -61.1% | 945 | $2K |
"% of holder's portfolio" is GANX's weight in each manager's 13F, not the share of Gain Therapeutics Inc. the manager owns.